(Q45988434)

18 December 2017

editorial

0 references

title

Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. (English)

1 reference

18 December 2017

author name string

Judd W Moul

series ordinal

1

1 reference

18 December 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

18 December 2017

number of pages

3

1 reference

inferred from page(s)

published in

Cancer

1 reference

18 December 2017

volume

115

1 reference

18 December 2017

page(s)

3376-3378

1 reference

18 December 2017

issue

15

1 reference

18 December 2017

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24393

Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24393

Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24393

7 January 2021

A re-assessment of the role of combined androgen blockade for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24393

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24393

7 January 2021

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24393

7 January 2021

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24393

7 January 2021

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24393

7 January 2021

Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24393

7 January 2021

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24393

7 January 2021

Identifiers

DOI

10.1002/CNCR.24393

1 reference

18 December 2017

PubMed ID

19484788

1 reference

18 December 2017